KR20220018959A - 6,8-비스-벤질티오-옥타노산을 사용한 림프종 치료를 위한 치료 방법 및 조성물 - Google Patents

6,8-비스-벤질티오-옥타노산을 사용한 림프종 치료를 위한 치료 방법 및 조성물 Download PDF

Info

Publication number
KR20220018959A
KR20220018959A KR1020217033115A KR20217033115A KR20220018959A KR 20220018959 A KR20220018959 A KR 20220018959A KR 1020217033115 A KR1020217033115 A KR 1020217033115A KR 20217033115 A KR20217033115 A KR 20217033115A KR 20220018959 A KR20220018959 A KR 20220018959A
Authority
KR
South Korea
Prior art keywords
lymphoma
administered
bis
benzylthio
octanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217033115A
Other languages
English (en)
Korean (ko)
Inventor
티모시 에스. 파디
제프리 에델슨
아리엘라 노이
자네타 라마르
Original Assignee
라파엘 파마슈티컬스, 인코포레이티드
메모리얼 슬로안 케터링 캔서 센터
웨이크 포리스트 유니버시티 헬스 사이언시즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라파엘 파마슈티컬스, 인코포레이티드, 메모리얼 슬로안 케터링 캔서 센터, 웨이크 포리스트 유니버시티 헬스 사이언시즈 filed Critical 라파엘 파마슈티컬스, 인코포레이티드
Publication of KR20220018959A publication Critical patent/KR20220018959A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217033115A 2019-03-19 2020-03-19 6,8-비스-벤질티오-옥타노산을 사용한 림프종 치료를 위한 치료 방법 및 조성물 Pending KR20220018959A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820767P 2019-03-19 2019-03-19
US62/820,767 2019-03-19
PCT/US2020/023537 WO2020191144A1 (en) 2019-03-19 2020-03-19 Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid

Publications (1)

Publication Number Publication Date
KR20220018959A true KR20220018959A (ko) 2022-02-15

Family

ID=72519349

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217033115A Pending KR20220018959A (ko) 2019-03-19 2020-03-19 6,8-비스-벤질티오-옥타노산을 사용한 림프종 치료를 위한 치료 방법 및 조성물

Country Status (11)

Country Link
US (1) US20220151994A1 (https=)
EP (1) EP3941453A4 (https=)
JP (1) JP2022525779A (https=)
KR (1) KR20220018959A (https=)
CN (1) CN114040758A (https=)
AU (1) AU2020240091A1 (https=)
BR (1) BR112021018138A2 (https=)
CA (1) CA3133101A1 (https=)
MX (1) MX2021011250A (https=)
TW (1) TW202102211A (https=)
WO (1) WO2020191144A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121645A1 (en) * 2018-12-20 2020-06-25 Rafael Pharmaceuticals, Inc. Oral therapy using 6,8-bis-benzylthio-octanoic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives

Also Published As

Publication number Publication date
WO2020191144A1 (en) 2020-09-24
AU2020240091A1 (en) 2021-09-30
EP3941453A4 (en) 2022-12-28
CA3133101A1 (en) 2020-09-24
JP2022525779A (ja) 2022-05-19
BR112021018138A2 (pt) 2021-11-16
TW202102211A (zh) 2021-01-16
MX2021011250A (es) 2022-02-11
US20220151994A1 (en) 2022-05-19
EP3941453A1 (en) 2022-01-26
CN114040758A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
CA2926771C (en) Cancer treatment with combination of plinabulin and taxane
JP6360438B2 (ja) 癌の治療
JP2020515519A (ja) 皮下ｈｅｒ２抗体製剤
EP3834889A1 (en) Treating myelomas
KR20190025733A (ko) 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
US20250275955A1 (en) Use of tivozanib to treat subjects with refractory cancer
JP2013521338A (ja) 小細胞肺癌を治療するための方法
KR20220018959A (ko) 6,8-비스-벤질티오-옥타노산을 사용한 림프종 치료를 위한 치료 방법 및 조성물
AU2016259775A1 (en) Cabazitaxel and its use for treating cancer
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
JP2020172471A (ja) ヒト化抗ヒトｃｄ２６抗体を含有する医薬組成物
WO2025250888A1 (en) Resiquimod in combination with a pd-1 or pd-l1 antagonist for treating cancer
CN109939094B (zh) 用于治疗胰腺癌的治疗性组合物
US20240016805A1 (en) Therapeutic methods and compositions for treating pancreatic cancer using devimistat
Bäckman et al. Conversion from Twice (Prograf) to Once Daily Administration of Tacrolimus (Advagraf) Regimen in Renal or Liver Transplant Recipients; An Open Multicenter Trial: 665
Todeschini et al. Advagraf vs. Prograf as Immunosuppressive Therapy in De Novo Renal Transplant Immunosuppressive Therapy: A Single Centre Experience: 714
Kim et al. Comparison Between Horse and Rabbit Antithymocyte Globulin as an Induction Agent in Kidney Transplantation: A Single Center Experience: 695

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250530

Patent event code: PE09021S01D